For cubby hole now the same team of 22 staffers will handle both projects, she adds, but eventually

Fierce Biomarkers Fierce BiotechResearch Fierce Biotech Fierce BiotechIT Fierce cubby hole CRO Fierce Diagnostics Fierce DrugDelivery Fierce MedicalDevices Fierce Pharma Fierce PharmaManufacturing Fierce Vaccines More Fierce Network sites
Free Daily Biotech Industry cubby hole Newsletter Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, cubby hole and Key Regulatory Issues sent straight to your Inbox. Join over 100,000 biotech professionals who subscribe to FierceBiotech for FREE!
NIH to open genomic data of HeLa cells to researchers by Emily Mullin In pharma, incremental innovation lives on by David Grainger NIH confirms it is shelving India drug trials in wake of new regs by John Carroll Industry Voices cubby hole More Commentary FEATURES
After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million cubby hole venture round designed to get her crew into the clinic with a lead antibody program, while a separate cubby hole project is being spun out into a new biotech that she will also direct.
Initially, iPierian had assembled a stellar group of stem cell experts to help guide the company into one of the hottest R&D fields at the time: stem cells. But despite all the talent, cubby hole iPierian never achieved liftoff, eventually seeing a series of CEOs come and go through the revolving doors. After Stagliano came in two years ago, though, and iPierian was restructured, she quickly set her sights on an antibody that targeted the tau protein and another antibody that zeroed in on the complement pathway, with potential in orphan diseases.
Now iPierian will be dedicated to following the tau target cubby hole for Alzheimer's , one of the biggest and most challenging major market quests in biotech, while True North takes the rare-disease development strategy for a much more narrowly defined patient population.
"It's all good news," cubby hole Stagliano tells FierceBiotech cubby hole . "We ended up having two very interesting and unique molecules, which we continued to advance over the past year. We realized cubby hole that it was a very clear decision that each represented unique partnering opportunities and different investors."
The tau project should generate an IND in 2014, she says, with a complement pathway IND coming in about 18 months. Tau has become the focus of a few biotech companies around the world, though most R&D projects have been targeting beta amyloid as a likely cause of the memory-wasting disease, which remains a mystery that has yet to be cracked by some of the top brains in global drug research. The complement system has three pathways, Stagliano explains. The True North antibody blocks the activation of the classic pathway, which drives a number of autoimmune diseases.
For cubby hole now the same team of 22 staffers will handle both projects, she adds, but eventually their paths will diverge. "That's where the beauty of two companies presents cubby hole itself," says the CEO. The Alzheimer's space is ripe for a partnership, and True North may require more venture money to go after orphan diseases.
"Under Nancy Stagliano's leadership over the last two years, there has been remarkable progress in transforming the proprietary stem cell platform of iPierian into meaningful cubby hole drug development programs to form the foundation for business plans in two exciting therapeutic areas," said Beth Seidenberg, a partner at Kleiner Perkins Caufield & Byers, in a statement.
In other financings , Arsanis raised $20 million in a Series B round to advance a pipeline of antibody treatments against infectious diseases. With antibody discovery from founding partner Adimab cubby hole in Lebanon, cubby hole NH, the Vienna, Austria, biotech startup has a lead antibody cocktail called ASN-100 for severe hospital-associated Staphylococcus aureus infections, the company said on Tuesday. New investor NeoMed Management led the second-round financing, which included support from previous backers and Adimab investors OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences. The influx of capital comes as Arsanis works toward initial clinical testing of ASN-100.
More Series B action out of Europe: Mind-NRG, a biotech startup based in Geneva, Switzerland, has found about $8 million from early backer Index Ventures and new investor LRM, which led the round. The company plans to use the funding to understand the mechanism of a potentially neuroprotective factor called NRG-101 in Parkinson's disease. The experimental therapeutic, discovered by Germany's ProteoSys, has the potential to treat early-stage cubby hole cases of Parkinson's, Alzheimer's disease and other neurodegenerative ailments.
FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more. Subscribe to our free daily email and join the largest, most influential biotechnology news audience in the world. Sign up to